Sale

Genitourinary Drugs Market

Global Genitourinary Drugs Market Share, Size, Analysis, Growth: By Indications: Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Others; By Drug Type; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Genitourinary Drugs Market Outlook

The global genitourinary drugs market reached a value of USD 48.46 billion in 2023, driven by the increasing prevalence of urinary tract infections across the globe. The market size is anticipated to grow at a CAGR of 3.1% during the forecast period of 2024-2032 to achieve a value of USD 63.78 billion by 2032.

 

genitourinary drugs market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Trends in the Market

The genitourinary system comprises of the kidneys, ureter, bladder, urethra, and genital organs which are crucial for reproduction and eliminating waste from the body. The system’s functionality can be impaired by congenital anomalies, infections, iatrogenic injuries, hydronephrosis, cancer, trauma, and inflammation. Globally, there is a surge in demand for genitourinary medications as a result of the increasing number of people who have these conditions. Genitourinary medications are prescribed to treat disorders of the urinary tract, reproductive organs, and excretory system.

 

  • The genitourinary drugs market worldwide is anticipated to grow throughout the forecast period. One of the main factors propelling the market for genitourinary drugs is the increasing prevalence of genitourinary conditions like erectile dysfunction, ovarian cancer, sexually transmitted diseases, bladder cancer, and benign prostatic hyperplasia.
  • The leading companies in the market are concentrating on developing medication formulations that assist in treating patients with persistent prostate cancer who have grown resistant to standard chemotherapeutic and hormone treatment agents.
  • A number of multinational corporations are working with top biopharmaceutical companies to introduce next-generation treatments and boost their market share. This is helping in the genitourinary drugs market expansion, facilitating a notable increase in the number of pipeline medications that are currently undergoing late-stage clinical studies.
  • Further, it is expected that the demand for genitourinary medications would increase in the approaching years due to rising financing for research and development initiatives and advancements in the healthcare infrastructure supported by governmental and non- governmental bodies of many countries.

 

Global Genitourinary Drugs Market Analysis 

 

genitourinary drugs market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on indication, the market is divided into ovarian cancer, prostate cancer, bladder cancer, cervical cancer, erectile dysfunction, sexually transmitted diseases, interstitial cystitis, and benign prostatic hyperplasia, among others. The market on the basis of product is segmented into urologicals, hormonal therapy drugs, anti-infectives, and gynaecological, among others. The regional markets for genitourinary drugs can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global genitourinary drugs market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.  

 

  • Bristol-Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Pfizer Inc.
  • Others

 

Market Share by Indication

Prostate cancer is anticipated to account for a leading share of the market for genitourinary drugs. This can be attributed to its wide prevalence, and the vast spectrum of treatments used to treat prostate cancer, including immunotherapy drugs, radiopharmaceuticals, and anti-neoplastic medicines. 

 

The major causes of prostate cancer include an ageing population, obesity, diet, and family history. The genitourinary drugs market supports improved survival rates, slowed disease progression, and minimal side effects. Furthermore, it is projected that invasive operations won't be necessary in the future due to the developments in formulation techniques and next-generation therapies. 

 

Market Share by Region

The genitourinary drugs market growth is predicted to be dominated by North America because of the region's expanding health care infrastructure, rising awareness of genitourinary problems, and rising need for better therapies and treatments for genitourinary diseases. During the course of the forecast period, the market expansion is anticipated to be fuelled by the rising prevalence of erectile dysfunction or ED in the United States. 

 

During the projected period, the Asia Pacific market for genitourinary drugs is anticipated to expand at a profitable rate, fuelled by rising awareness in economies like China and India. The significant investments in research and development by major players and persistent efforts to market branded treatments at affordable prices are the driving forces for the market in the region. Rising disposable income will further increases the likelihood of using branded drugs, and ongoing improvements in healthcare infrastructure are also expected to support the market growth in the Asia Pacific. 

 

genitourinary drugs market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

Bristol-Myers Squibb Company, a multinational biopharmaceutical firm with headquarters in New York in the United States researches, develops, and distributes cutting-edge medications that aid patients in overcoming life-threatening illnesses. As part of its dedication to patient care, Bristol Myers Squibb works tirelessly to improve the quality of life for cancer patients as well as to define the future of cancer treatment. The business is renowned for its work in biological and pharmaceutical research.

 

Novartis AG, a Swiss corporation, is among the biggest producers of medications worldwide. Two significant Swiss pharmaceutical firms, Ciba-Geigy AG and Sandoz AG, combined to form Novartis in 1997. It offers medications for the treatment of infections, immunological disorders, ophthalmic and respiratory illnesses, cancer, cardiovascular diseases, dermatological issues, neurological disorders, and cancer.

 

F. Hoffmann-La Roche Ltd, a biotechnology business, with headquarters in Switzerland, creates medications and diagnostics to treat serious illnesses. It offers medications to treat conditions like cancer, autoimmune diseases, issues with central nervous systems, eye and vision problems, infectious diseases, and respiratory illnesses. Roche conducts research to find fresh approaches to preventing, diagnosing, and treating illnesses.

 

Other market players include Genentech, Inc. and Pfizer Inc., among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Indications
  • Drug Type
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Indication
  • Prostate Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Renal Cancer
  • Erectile Dysfunction
  • Urinary Tract Infections
  • Overactive Bladder
  • Sexually Transmitted Diseases
  • Interstitial Cystitis
  • Hematuria
  • Benign Prostatic Hyperplasia
  • Others
Breakup by Drug Type
  • Hormonal Therapy
  • Impotence Agents
  • Uterine Relaxants
  • Urinary Antispasmodics
  • Urinary pH Modifiers
  • Uterine Stimulants
  • Miscellaneous Genitourinary
  • Tract Agents
  • Others
Breakup by Route of Administration
  • Oral
  • Parentals
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Astellas Pharma.
  • Allergan
  • GlaxoSmithKline plc.
  • Antares Pharma
  • Eli Lilly and Company
  • Bayer AG, Merck KGaA
  • Abbott
  • Bristol-Myers Squibb Company
  • Genentech
  • F. Hoffman-La Roche Ltd.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca
  • Advanz Pharmaceutical

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Genitourinary Drugs Market Overview

    3.1    Global Genitourinary Drugs Market Historical Value (2017-2023) 
    3.2    Global Genitourinary Drugs Market Forecast Value (2024-2032)
4    Global Genitourinary Drugs Market Landscape
    4.1    Global Genitourinary Drugs Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Genitourinary Drugs Product Landscape
        4.2.1    Analysis by Indications
        4.2.2    Analysis by Drug Type
        4.2.3    Analysis by Distribution Channel
5    Global Genitourinary Drugs Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Genitourinary Drugs Market Segmentation 
    6.1    Global Genitourinary Drugs Market by Indications
        6.1.1    Market Overview
        6.1.2    Prostate Cancer
        6.1.3    Ovarian Cancer
        6.1.4    Bladder Cancer
        6.1.5    Cervical Cancer
        6.1.6    Renal Cancer
        6.1.7    Erectile Dysfunction
        6.1.8    Urinary Tract Infections
        6.1.9    Overactive Bladder
        6.1.10    Sexually Transmitted Diseases
        6.1.11    Interstitial Cystitis
        6.1.12    Hematuria
        6.1.13    Benign Prostatic Hyperplasia
        6.1.14    Others
    6.2    Global Genitourinary Drugs Market by Drug Type
        6.2.1    Market Overview
        6.2.2    Hormonal Therapy
        6.2.3    Impotence Agents
        6.2.4    Uterine Relaxants
        6.2.5    Urinary Antispasmodics
        6.2.6    Urinary pH Modifiers
        6.2.7    Uterine Stimulants
        6.2.8    Miscellaneous Genitourinary
        6.2.9    Tract Agents
        6.2.10    Others
    6.3    Global Genitourinary Drugs Market by Route of Administration
        6.3.1    Market Overview
        6.3.2    Oral
        6.3.3    Parentals
    6.4    Global Genitourinary Drugs Market by Distribution Channel
        6.4.1    Market Overview
        6.4.2    Hospital Pharmacy
        6.4.3    Online Pharmacy
        6.4.4    Retail Pharmacy
    6.5    Global Genitourinary Drugs Market by Region
        6.5.1    Market Overview
        6.5.2    North America 
        6.5.3    Europe
        6.5.4    Asia Pacific
        6.5.5    Latin America
        6.5.6    Middle East and Africa
7    North America Genitourinary Drugs Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Genitourinary Drugs Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Genitourinary Drugs Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Genitourinary Drugs Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Genitourinary Drugs Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Clinical Trials Analysis
    14.1     Analysis by Trial Registration Year 
    14.2    Analysis by Trial Status 
    14.3    Analysis by Trial Phase 
    14.4    Analysis by Therapeutic Area 
    14.5    Analysis by Geography 
15    Funding Analysis
    15.1    Analysis by Funding Instances
    15.2    Analysis by Type of Funding
    15.3    Analysis by Funding Amount
    15.4    Analysis by Leading Players
    15.5    Analysis by Leading Investors
    15.6    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Supplier Landscape
    18.1    Pfizer Inc.
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Astellas Pharma.
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    Allergan
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    GlaxoSmithKline plc.
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    Antares Pharma
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Eli Lilly and Company
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Bayer AG, Merck KGaA
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    Abbott
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    Bristol-Myers Squibb Company
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    Genentech 
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    F. Hoffman-La Roche Ltd.
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    Novartis AG
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    Teva Pharmaceutical Industries Ltd.
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14    AstraZeneca
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions
        18.14.5    Certifications
    18.15    Advanz Pharmaceutical
        18.15.1    Financial Analysis
        18.15.2    Product Portfolio
        18.15.3    Demographic Reach and Achievements
        18.15.4    Mergers and Acquisitions
        18.15.5    Certifications
19    Global Genitourinary Drugs Market - Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment 
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market of genitourinary drugs attained a value of USD 48.46 billion.

The market is anticipated to grow at a CAGR of 3.1% during the forecast period of 2024-2032 to reach a value of USD 63.78 billion by 2032.

The major drivers of the genitourinary drugs market include rising frequency of genitourinary illnesses, improvements in the healthcare infrastructure, and increasing awareness about genitourinary disorders.

Increasing funding for research and development, rise in the number of pipeline drugs in late-stage clinical trials, and launch of next-generation therapeutics are the key industry trends propelling the growth of the market.

The major players in the industry are Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Genentech, Inc., and Pfizer Inc., among others.

Genitourinary drugs are used to treat infections to the genitourinary tract, congenital abnormalities, trauma, cancer, inflammation, iatrogenic injuries, and other ailments that cause damage to genitourinary organs.

The various genitourinary drug products are urologicals, hormonal therapy drugs, anti-infectives, and gynaecological, among others.

All organs involved in reproduction as well as those involved in urine production and excretion make up the genitourinary system, for example, fallopian tubes, kidneys, prostate, and bladder.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER